<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60303">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01792635</url>
  </required_header>
  <id_info>
    <org_study_id>B1731003</org_study_id>
    <nct_id>NCT01792635</nct_id>
  </id_info>
  <brief_title>A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus</brief_title>
  <official_title>A 6-Week Phase 2a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Assess Safety, Tolerability And Pharmacodynamics Of Oral PF-05175157 As Monotherapy In Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the safety, tolerability and pharmacodynamics of 6 weeks of
      oral doses of PF-05175157 provided as monotherapy in subjects with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Glucose infusion rates</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Endogenous glucose production</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Endogenous glucose production measured by means of euglycemic hyperinsulinemic clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Whole-body glucose uptake</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of appearance of glucose in fasting state and during insulin infusions</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose infusion rates at steady-state during Step 1 and Step 2 insulin infusions</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Part A (Pilot Study)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05175157</intervention_name>
    <description>PF-05175157 will be administered at 200 mg twice a day for 43 days.</description>
    <arm_group_label>Monotherapy (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets matched to PF-05175157 will be administered twice a day for 43 days.</description>
    <arm_group_label>Monotherapy (Part B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have been diagnosed with type 2 diabetes mellitus by a medical
             professional according to the American Diabetes Association guidelines.

          -  Hemoglobin A1c of ≥7 and ≤10.0% in subjects who are metformin-naive or have not taken
             metformin for 2 months or Hemoglobin A1c of ≥6.5 and ≤9.5% in subjects who are
             metformin-naïve and are taking SU or DPP-IVi which is washed off or taking metformin
             and are willing to discontinue metformin in a 8-week washout period.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine (other
             than T2DM and hypothyroidism), gastrointestinal, cardiovascular, pulmonary, hepatic,
             psychiatric or neurologic disease.

          -  A waist circumference which makes fitting imto the bore of the MR scanner impossible.

        Subjects with history of dry eye, known ocular or systemic disease that affect the sclera
        or cornea.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1731003&amp;StudyName=A%206-Week%20Study%20Of%20PF-05175157%20In%20Type%202%20Diabetes%20Mellitus</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>December 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Safety &amp; Tolerability</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
